Big Pharma's sale of Old Drug has increased

the acquisition of domestic sales rights of Korea Pharmaceutical

Bonviva= Jeil, Omnaris=SK Chemical, Vimovo=LG Chemical

Most drugs with changed global copyright have been released for a long time, so their competitiveness remains unknown

The number of domestic pharmaceutical companies acquiring domestic copyrights of original drugs has been increasing recently.

 

This is a case in which domestic copyrights have also changed as most original developers sold global copyrights as part of restructuring.

 

Jeil announced on the 8th that it will exclusively supply Bonviva and Bonviva plus, treatments for osteoporosis, in Korea.

 

Bonviva originally entered the domestic market with permission from Roche, a multinational pharmaceutical company.

 

As global copyright was transferred to British pharmaceutical company Aetna Pharma in 2017, domestic copyrights are also changing.

 

Since 2015, Handok has been selling and obtaining permission rights, but it has recently been transferred to Jeil.

 

Pharmanovia, a subsidiary of Aetna Pharm, which has global copyright, signed an exclusive sales contract with Jeil when it established a domestic branch.

 

Currently, Bonvia is licensed by Jeil Pharmaceutical, and Bonviva Plus is registered as a licensed company by Alvogen Korea, a developer.

 

However, reimbursed pharmaceutical companies are still in Korea and Germany.

 

In the future, there is a high possibility that pharmaceutical companies will also be transferred to Jeil through transfer and transfer.

 

SK Chemicals recently acquired domestic copyright for Omnaris nasal spray, an allergic rhinitis treatment.

 

Omnaris nasal spray was introduced and sold by Handok from Nycomed, Switzerland, but domestic copyrights were transferred to Takeda in 2011 and AstraZeneca in 2015.

 

AstraZeneca sold Omnaris' global copyright to Covis Pharma in 2018, and the final destination of domestic copyrights was SK Chemicals.

 

Omnaris was completely transferred to SK Chemicals through transfer and transfer of permission and rights.

 

SK Chemicals also acquired the domestic license for AstraZeneca's asthma treatment Alvesco.

 

LG Chem also acquired the domestic copyright of the anti-inflammatory painkiller Vimovo from AstraZeneca.

 

Vimovo is an NSAIDs-PPI complex released in Korea by AstraZeneca in 2012.

 

LG Chem Participates in Co-promotion Recently, both the right to permit and the right to pay have been transferred.

 

Vimovo's global copyright was also sold to German pharmaceutical company Grünenthal in 2018.

 

Although domestic pharmaceutical companies have acquired exclusive sales rights in Korea beyond co-promotion with overseas pharmaceutical companies, it is too much to lead to a significant increase in profits.

 

This is because it is an old drug that is less competitive than other drugs because it has been released for a long time.

 

Moreover, pharmaceutical companies with global copyrights may terminate their domestic copyright contracts, which cannot be considered completely attributed to assets.